Pol F. Boudes

Pol F. Boudes

M.D., Former Chief Medical OfficeratGalectin Therapeutics· In proxies 2022–2023

Pay in FY2022Galectin Therapeutics stock -45.4% the same year

Pol F. Boudes was paid $794.6K in FY2022 (Dec). Galectin Therapeutics stock fell 45.4% that year.

Pay$100 in the stock at the end of FY21 → $55
Pay is from the Summary Compensation Table of each Galectin Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Galectin TherapeuticsPublic company · 4 yr
    • M.D., Former Chief Medical Officer2022 – Present · 4 yrStock in role +61%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?